Sign up for free insights newsletter
Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

DRREDDYNSE

Need professional-grade analysis? Visit stockanalysis.com

₹1,259.60
-3.03%
End of day
Market Cap

$1.10T

P/E Ratio

19.42

Employees

27,811

Dividend Yield

0.60%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino5.85-0.490.34-0.100.55
Calmar53.62-1.980.50-0.135.06
Sharpe2.97-0.350.21-0.070.26
Omega1.770.951.061.011.09
Martin-3.811.24-0.29-0.56
Ulcer0.782.013.975.013.67

Dr. Reddy's Laboratories Limited (DRREDDY) Price Performance

Dr. Reddy's Laboratories Limited (DRREDDY) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR1259.60, down 3.03% from the previous close.

Over the past year, DRREDDY has traded between a low of INR1157.20 and a high of INR1325.50. The stock has gained 5.1% over this period. It is currently 8.8% above its 52-week low.

Dr. Reddy's Laboratories Limited has a market capitalization of $1.10T, with a price-to-earnings ratio of 19.42 and a dividend yield of 0.60%.

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Company Info

Exchange
NSE
Currency
INR
Country
India

Financial Metrics

Revenue (TTM)
$345.83B
EBITDA
$84.79B
Profit Margin
16.36%
EPS (TTM)
67.93
Book Value
447.25

Technical Indicators

52 Week High
₹1,337.30
52 Week Low
₹1,148.40
50 Day MA
₹1,250.37
200 Day MA
₹1,263.03
Beta
0.31

Valuation

Trailing P/E
19.42
Forward P/E
25.58
Price/Sales
3.18
Price/Book
2.96
Enterprise Value
$1.09T